Search research articles
Contact Us
Filters
Showing results (21-30 of 24) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 24 results.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
December 2, 2024
Rare Spinocerebellar Ataxia Types in Canada: A Case Series and Review of the Literature
Sohaila Alshimemeri, Lamya Alsaghan, Danah Abo Alsamh, et al.
Neurology
|
September 29, 2017
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Ronald B Postuma, Julius Anang, Amelie Pelletier, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 16, 2004
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)
Sarah Furtado, Haydeh Payami, Paul J Lockhart, et al.
JAMA Neurology
|
November 17, 2015
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials
, Kevin Michael Biglan, Ira Shoulson, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 24) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 24 results.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|
December 2, 2024
Rare Spinocerebellar Ataxia Types in Canada: A Case Series and Review of the Literature
Sohaila Alshimemeri, Lamya Alsaghan, Danah Abo Alsamh, et al.
Neurology
|
September 29, 2017
Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial
Ronald B Postuma, Julius Anang, Amelie Pelletier, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
June 16, 2004
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)
Sarah Furtado, Haydeh Payami, Paul J Lockhart, et al.
JAMA Neurology
|
November 17, 2015
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials
, Kevin Michael Biglan, Ira Shoulson, et al.
Page
of 3